Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH 2017 | Expanding trials using bispecifics

John DiPersio • 5 Oct 2017
ESH 2017
Acute Myeloid Leukemia

This is an exciting time for leukemia research, with the latest research using bispecifics revealing positive outcomes for patients. Here, Prof. John DiPersio, MD, PhD of Washington University School of Medicine, Washington, WA describes future plans to expand a study using bispecifics to treat patients with acute myeloid leukemia. This interview was recorded at the International Conference on Acute Myeloid Leukaemia 2017, Estoril, Portugal by the European School of Haematology (ESH).

More from John DiPersio

4:02
Identifying the optimal toxic payloads for antibody-based SCT conditioning using SAv-drug conjugates
John DiPersio • 21 Feb 2023
5:08
LBA: CD33 CRISPR/Cas9 gene-edited donor allograft in patients with AML at risk of relapse post-HSCT
John DiPersio • 21 Feb 2023
4:13
ALL highlights: tisa-cel reinfusion in B-ALL & targeting CD5 and CD7 with CAR-Ts in T-ALL
John DiPersio • 21 Feb 2023
4:19
Advantages & concerns associated with the use of ADC-based conditioning in SCT recipients
John DiPersio • 21 Feb 2023

Related Videos

1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
2:25
Optimizing haplo-SCT for the treatment of AML
Arnon Nagler • 16 Apr 2024
3:34
Total marrow and lymphoid irradiation plus cyclophosphamide & etoposide in poor-risk acute leukemias
Anthony Stein • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals